Incorporation of paclitaxel-based hyperthermic intraperitoneal chemotherapy in patients with advanced-stage ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery: a protocol-based pilot study.
- Author:
Yong Jae LEE
1
;
Jung Yun LEE
;
Min Soo CHO
;
Eun Ji NAM
;
Sang Wun KIM
;
Sunghoon KIM
;
Young Tae KIM
Author Information
- Publication Type:Original Article
- Keywords: Ovarian Neoplasms; Hyperthermic Intraperitoneal Chemotherapy; Surgery; Paclitaxel; Drug Therapy
- MeSH: Cohort Studies; Disease-Free Survival; Drug Therapy*; Humans; Laparoscopy; Mortality; Neoplasm Metastasis; Ovarian Neoplasms*; Paclitaxel; Pilot Projects*; Tumor Burden
- From:Journal of Gynecologic Oncology 2019;30(1):e3-
- CountryRepublic of Korea
- Language:English
- Abstract: OBJECTIVES: We conducted a protocol-based cohort study to evaluate the outcomes of interval debulking surgery (IDS) followed by paclitaxel-based hyperthermic intraperitoneal chemotherapy (HIPEC) for the treatment of advanced-stage ovarian cancer. METHODS: From October 2015 to May 2018, 65 patients with stages IIIC–IV ovarian cancer were treated according to the study protocol. HIPEC was performed with paclitaxel (175 mg/m2) for 90 minutes, only in cases of optimal cytoreduction. RESULTS: Of 65 patients, 40 (61.5%) patients underwent neoadjuvant chemotherapy (NAC), 34 (52.3%) patients had a high tumor burden with a Fagotti score ≥8 at diagnostic laparoscopy, and 6 (9.2%) had definite stage IV metastasis and/or poor performance status before NAC. Twenty-seven (41.5%) patients underwent IDS followed by HIPEC. The mean duration of IDS with HIPEC was 543.8 (range, 277.0–915.0) minutes. Grade III/IV perioperative complications occurred in 7.4% (n=2)/3.7% (n=1) of patients and no cases of mortality were reported within 30 days postoperatively. The median progression-free survival was 21.3 months, and the median overall survival was not reached for those who received HIPEC. CONCLUSIONS: According to our study protocol, IDS followed by paclitaxel-based HIPEC as a first-line treatment appears to be feasible and safe for the treatment of advanced-stage ovarian cancer. Further evaluations of this procedure are required to assess its survival benefits.
